Entrada Therapeutics (NASDAQ:TRDA) CFO Kory James Wentworth Sells 5,089 Shares

Entrada Therapeutics, Inc. (NASDAQ:TRDA) CFO Kory James Wentworth sold 5,089 shares of the stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $13.00, for a total transaction of $66,157.00. Following the sale, the chief financial officer directly owned 132,898 shares of the company’s stock, valued at $1,727,674. The trade was a 3.69% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Kory James Wentworth also recently made the following trade(s):

• On Tuesday, March 10th, Kory James Wentworth sold 11,388 shares of Entrada Therapeutics stock. The stock was sold at an average price of $13.02, for a total value of $148,271.76.
• On Wednesday, March 4th, Kory James Wentworth sold 7,988 shares of Entrada Therapeutics stock. The shares were sold at an average price of $12.25, for a total value of $97,853.00.

Entrada Therapeutics Price Performance

Entrada Therapeutics stock traded up $0.30 during midday trading on Wednesday, reaching $13.50. The company’s stock had a trading volume of 210,880 shares, compared to its average volume of 236,376. The stock has a market capitalization of $516.78 million, a P/E ratio of -3.90 and a beta of -0.12. The stock’s 50-day simple moving average is $11.16 and its 200-day simple moving average is $8.83. Entrada Therapeutics, Inc. has a 52-week low of $4.93 and a 52-week high of $13.66.

Entrada Therapeutics (NASDAQ:TRDA) last released its earnings results on Thursday, February 26th. The company reported ($0.94) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.32) by $0.38. The firm had revenue of $1.30 million for the quarter, compared to the consensus estimate of $7.41 million. Entrada Therapeutics had a negative return on equity of 39.83% and a negative net margin of 565.48%. As a group, equities research analysts expect that Entrada Therapeutics, Inc. will post 1.12 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Entrada Therapeutics

A number of hedge funds have recently made changes to their positions in TRDA. Millennium Management LLC lifted its stake in shares of Entrada Therapeutics by 391.2% in the third quarter. Millennium Management LLC now owns 836,609 shares of the company’s stock worth $4,852,000 after buying an additional 666,287 shares in the last quarter. Citadel Advisors LLC grew its stake in Entrada Therapeutics by 234.5% during the 3rd quarter. Citadel Advisors LLC now owns 335,741 shares of the company’s stock valued at $1,947,000 after acquiring an additional 235,384 shares in the last quarter. Baker BROS. Advisors LP raised its holdings in Entrada Therapeutics by 4.3% in the 4th quarter. Baker BROS. Advisors LP now owns 5,072,730 shares of the company’s stock valued at $52,148,000 after acquiring an additional 206,911 shares during the last quarter. Qube Research & Technologies Ltd raised its holdings in Entrada Therapeutics by 115.3% in the 3rd quarter. Qube Research & Technologies Ltd now owns 287,873 shares of the company’s stock valued at $1,670,000 after acquiring an additional 154,143 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its stake in Entrada Therapeutics by 4,767.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 148,212 shares of the company’s stock worth $860,000 after purchasing an additional 145,167 shares in the last quarter. Institutional investors and hedge funds own 86.39% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on TRDA shares. Guggenheim upgraded Entrada Therapeutics to a “strong-buy” rating in a research report on Wednesday, February 11th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Entrada Therapeutics in a research note on Monday, December 29th. Wall Street Zen raised shares of Entrada Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Oppenheimer assumed coverage on shares of Entrada Therapeutics in a research note on Wednesday, January 28th. They issued an “outperform” rating and a $21.00 target price for the company. Finally, HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Entrada Therapeutics in a report on Wednesday, February 18th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $18.50.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.